Navigation Links
Patch Form of HRT Poses Less Clotting Risks Than Pill Does
Date:5/22/2008

Analysis finds pill more than doubles risk while patch only increases it slightly

THURSDAY, May 22 (HealthDay News) -- Women who take hormone replacement therapy via skin patches may face a lower risk of blood clots than women who take the therapy orally.

The new finding could change the risk-benefit ratio for women who are considering hormone therapy to relieve hot flashes, night sweats and other symptoms of menopause.

"One main clinical implication is to consider transdermal rather than oral estrogen for women at high cardiovascular risk in order to avoid thrombosis [blood clots], which is the main harmful effect of short-term hormone therapy," said Dr. Pierre-Yves Scarabin, director of research at the National Institute of Health and Medical Research in France, and senior author of a study published in the May 23 online issue of the British Medical Journal.

Previous studies have found an increased risk not only of blood clots, but also coronary heart disease and breast cancer among postmenopausal women who take hormone replacement therapy (HRT).

But, according to background information in the paper, no one has assessed how high the increased risk is, or whether the risk varies with the type of therapy.

Scarabin and his colleagues reviewed data from eight observational studies and nine randomized controlled trials on HRT and venous thromboembolism (VTE), a potentially fatal blood clot in the vein.

Pool results indicated that the risk of VTE was 2.5 times higher in women taking oral estrogen compared to women taking no estrogen. The risk was most pronounced during the first year of treatment and in women who were overweight or predisposed toward developing blood clots.

By contrast, women currently using the patch had only a slightly elevated risk compared to women taking no estrogen.

Women who had stopped taking HRT saw their risk return to normal.

According to the authors, the increased risk translates into an additional 1.5 events per 1,000 women per year.

Most of the data came from existing observational trials, however, not the gold-standard randomized trials, so the findings should be interpreted with caution, the authors warned.

Other experts agreed.

"It's observational and very interesting, but clearly more studies need to be done," said Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City. "Maybe this opens the door for a way to give hormones more safely to those who need it."

More information

Visit the National Heart, Lung, and Blood Institute for more on hormone replacement therapy.



SOURCES: Pierre-Yves Scarabin, M.D., director, research, National Institute of Health and Medical Research, and cardiovascular epidemiology section, Paul Brousse Hospital, Villejuif, France; Suzanne Steinbaum, D.O., director, women and heart disease, Lenox Hill Hospital, New York City; May 23, 2008, British Medical Journal


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
2. Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine
3. Study Finds Single Dose of Iomai Patch With Pandemic Flu Vaccine Achieves Protective Levels
4. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
5. PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches
6. Iomai Study Shows Self-Applied Travelers Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch
7. Ringing endorsement: Women prefer contraceptive ring over patch
8. FDA Warns Clot Risk Higher in Birth Control Patch Than Pill
9. FDA Renews Warnings on Pain-Relief Patch
10. Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches
11. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patch Form of HRT Poses Less Clotting Risks Than Pill Does 
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: